Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | PIP4K2A | P48426 | 7/20 | 0.35 |
| ▸ | PIP4K2B | P78356 | 6/20 | 0.35 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.32 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745325 | 1.00 | CYP3A4 (0.49) | CYP3A4PIP4K2APIP4K2BPIP4K2CTEAD2 | |
| SCHEMBL2128628 | 0.85 | CYP3A4 (0.68) | CYP3A4PIP4K2APIP4K2BPIP4K2CIKBKB | |
| SCHEMBL1542176 | 0.85 | CYP3A4 (0.68) | CYP3A4PIP4K2APIP4K2BPIP4K2CIKBKB | |
| SCHEMBL2520553 | 0.82 | CYP3A4 (0.51) | CYP3A4PIP4K2APIP4K2BPIP4K2CTDP2 | |
| SCHEMBL2520555 | 0.82 | CYP3A4 (0.51) | CYP3A4PIP4K2APIP4K2BPIP4K2CTDP2 | |
| SCHEMBL2491321 | 0.82 | CYP3A4 (0.72) | CYP3A4PIP4K2APIP4K2BIKBKBCHUK | |
| SCHEMBL2491324 | 0.82 | CYP3A4 (0.72) | CYP3A4PIP4K2APIP4K2BIKBKBCHUK | |
| SCHEMBL1542956 | 0.82 | CYP3A4 (0.52) | CYP3A4PIP4K2APIP4K2BPIP4K2CTDP2 | |
| SCHEMBL2128404 | 0.82 | CYP3A4 (0.52) | CYP3A4PIP4K2APIP4K2BPIP4K2CTDP2 | |
| SCHEMBL1764738 | 0.80 | CYP3A4 (0.64) | CYP3A4IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | claimed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CYP3A4 978/4885PIP4K2A 3173/4885PIP4K2B 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.